Index of microcirculatory resistance-guided management in angina: design and rationale of the DECISIONING trial
Study context
- Population
- Participants with angina and at least one angiographic lesion ≥50%, with fractional flow reserve (FFR) and initial index of microcirculatory resistance (IMR) measured before randomization275 participants randomized as of September 19, 2026, enrollment ongoing
- Participants
- planned n=280 participants
- Planned comparison
- Disclosure of IMR with protocol-guided personalized management compared with concealed IMR and usual care
Methodological detailsdesign and rationale, stratified by center and initial IMR (<25 or ≥25), 1:1 randomization, open-label to participants and treating clinicians; initial IMR concealed from control participants and clinicians, blinded centralized follow-up and outcome assessment
- Design and rationale
- Stratified by center and initial IMR (<25 or ≥25)
- 1:1 randomization
- Open-label to participants and treating clinicians; initial IMR concealed from control participants and clinicians
- Blinded centralized follow-up and outcome assessment
No results yet. This paper sets out the design of a trial; its results are to come.
Further findings
Enrollment status · As of September 19, 2026
- Participants randomized
- 275
- Enrollment began
- March 31, 2022
- Final follow-up expected
- october 2028
- Enrollment toward 280 was ongoing
Original publication
Index of microcirculatory resistance-guided management in angina: design and rationale of the DECISIONING trial. Am Heart J. Published 4 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →